Contact Information: Contact: Dino Luzzi CEO Medivisor, Inc. 326 Walt Whitman Road Huntington Station, N.Y. 11746 Tel: 631.549.7100 http://www.medivisor.com
Albumax Has Been Approved by Medicaid in New York
| Source: Medivisor, Inc.
HUNTINGTON STATION, NY--(Marketwire - September 12, 2008) - Medivisor, Inc. (PINKSHEETS : MVSR )
announced today that Albumax has been approved by the New York State
Medicaid Office. Albumax has been approved under code B4155 as an enteral
product. The approval is significant in that it allows for Medicaid
reimbursement of costs for eligible patients using Albumax. Medicaid is
the largest source of funding for medical and health-related services for
people with limited income. It is an entitlement program that is jointly
funded by the states and federal government, and is managed by the states.
Among the groups of people served by Medicaid are eligible low-income
parents, children, seniors, and people with disabilities.
"Medicaid approval is an extremely important component in our marketing
initiative for the national launch of Albumax," said Mr. Dino Luzzi, CEO of
Medivisor, Inc. "Medicaid acceptance for Albumax certainly strengthens the
interest in the product, and increases the willingness of providers and
patients to use Albumax to increase blood albumin levels in kidney disorder
patients," continued Mr. Luzzi. An important component of the overall
initiative for Albumax is a very aggressive Internet marketing program that
consistently keeps Albumax in the marketplace. Patients and those in the
Medical Profession can now go to www.albumax.net to order or inquire about
the product.
Under a recently announced agreement with Cura Pharmaceutical Co., Inc.,
Medivisor is responsible for marketing and sales of Albumax, a whey protein
isolate formula that makes it easy for kidney disorder patients to reach
their daily requirements of high quality protein in their diet.
About Medivisor, Inc.
Medivisor, Inc., a rapidly growing developer of next-generation focus
driven marketing tools. The company is dedicated to providing technologies
that offer innovative and competitive advantages to the bioscience and
pharmaceutical markets and beyond. From pre-product development through
product launch and commercialization, Medivisor offers worldwide experience
in delivering effective and successful integrated marketing and creative
communications campaigns for the mutual benefit of its clients.
www.medivisor.com
Safe Harbor
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 (the "Act")
Additionally, words such as "seek," "intend," "believe," "plan,"
"estimate," "expect," "anticipate" and other similar expressions are
forward-looking statements within the meaning of the Act. Some or all of
the events or results anticipated by these forward-looking statements may
not occur. Factors that could cause or contribute to such differences
include the performance ability of the initial units in the field. Further
information on Medivisor risk factors is contained in its filings with the
Securities and Exchange Commission. Medivisor does not undertake any duty
nor does it intend to update the results of these forward-looking
statements.